| Drug name | Drug sensitivity | Evidence |
| 17-AAG | High-risk group | Sauvageot et al. [33] |
| AG-014699 (Rucaparib) | High-risk group | Zhang et al. [34] |
| Bortezomib | High-risk group | Su et al. [35] |
| Dasatinib | High-risk group | Alhalabi et al. [36] |
| Lapatinib | High-risk group | Yu et al. [37] |
| LY317615 | High-risk group | Graff et al. [38] |
| MG-132 | High-risk group | Li et al. [39] |
| OSI-930 | High-risk group | Yang et al. [40] |
| Paclitaxel | High-risk group | Yang et al. [41] |
| Pazopanib | High-risk group | Haraldsdottir et al. [42] |
| PD-0332991 | High-risk group | Michaud et al. [43] |
| Rapamycin | High-risk group | Le et al. [44] |
| Ruxolitinib | High-risk group | Delen et al. [45] |
| Temsirolimus | High-risk group | Kaley et al. [46] |
| TGX221 | High-risk group | Yang et al. [47] |
| Z-LLNle-CHO | High-risk group | Monticone et al. [48] |
| BMS-754807 | Low-risk group | Fuentes-Baile et al. [49] |
| FK866 | Low-risk group | Feng et al. [50] |
| Salubrinal | Low-risk group | He et al. [51] |